Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Preclinical efficacy of FG-3019 against diabetes-associated metabolic/cardiovascular complications

Nov. 18, 2005

EP4 agonism as a treatment for diabetic nephropathy

Nov. 17, 2005

New data support the use of sulodexide in the treatment of diabetic nephropathy

Nov. 16, 2005

Fuji Pharma and JCR dissolve codevelopment agreement for JR-013

Nov. 16, 2005

Cetilistat successfully completes U.S. study in obese subjects

Nov. 16, 2005

Phase III ferumoxytol program recommended to continue by DMC

Nov. 16, 2005

Agents for metabolic disorders prepared and tested

Nov. 15, 2005

A2A receptor agonists ameliorate renal NO production in diabetic nephropathy in rats

Nov. 15, 2005

TSP-2 gene therapy prevents TSP-1-mediated fibrogenesis in a diabetic nephropathy model

Nov. 15, 2005

Preclinical profile of a nonhormonal therapy for postmenopausal syndromes

Nov. 15, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
Regeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis
BioWorld
Regeneron Pharmaceuticals Inc. stuck with the tradition of releasing bad news on Friday afternoon and good news on Monday morning with a pair of announcements...